

Please join us for a Product Theater

Disease Characteristics, Treatments, and Outcomes: Recent Findings From a Large, Real-World, PAH Drug Registry

Friday, January 17, 2025
11:30 am - 12:30 pm

Atlantic Room
Hollywood Beach Marriott
Hollywood, Florida

Faculty



Nick Kim, MD

Section Chief, Pulmonary Vascular Medicine
University of California, San Diego
La Jolla, California

This consultant is a paid speaker for Johnson & Johnson.

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by restricted blood flow through the pulmonary vasculature ultimately leading to right heart failure.¹ This industry theater will feature Nick Kim, MD, a PAH thought leader, who will review recent real-world evidence from a large, multi-center, prospective, observational PAH drug registry.

1. McLaughlin VV, Shah SJ, Souza R, et al. *J Am Coll Cardiol.* 2015; 65:1976-1997.

This promotional educational activity is brought to you by Johnson & Johnson and is not certified for CME. The consultant is a paid speaker for Johnson & Johnson. The speaker is presenting on behalf of Johnson & Johnson and must present information in compliance with FDA requirements applicable to Johnson & Johnson.

This program/event is developed and offered by Johnson & Johnson. This is not an official program/event of the Cleveland Clinic.

Johnson&Johnson